Reduced Plasma Bradykinin and an Elevated Angiotensin converting enzyme/Bradykinin Ratio are Associated with Disease Severity in COVID-19: A Retrospective Study of 224 Severity-Stratified Patients
Medical Principles and Practice · 2026-11-05
DOI: 10.1159/mpp/adpag043 ↗Abstract
Abstract Objectives: Dysregulation of kallikrein-kinin system (KKS) has been suggested to play a role in the pathophysiology of Coronavirus disease 2019 (COVID-19) and contribute to COVID-19-related inflammation, coagulation, vasodilatation, and vascular permeability. Therefore, in the present study, plasma levels of bradykinin, a major KKS peptide, and angiotensin converting enzyme (ACE), a primary enzyme degrading bradykinin were investigated. Subjects and Methods: In this retrospective study, plasma bradykinin was measured by ELISA method in a stratified cohort of 224 COVID-19 patients spanning the full WHO severity range, from asymptomatic infection to critical illness. Unlike most previous studies limited to hospitalized patients, ACE was also quantified in the same specimens, enabling calculation of the ACE/bradykinin ratio. Results: Plasma bradykinin levels progressively decreased across the five severity strata. Severe/critical patients had significantly lower levels than asymptomatic/mild patients (p < 0.001), while mild pneumonia patients had lower levels than those with mild symptomatic disease (p < 0.001). Bradykinin levels did not differ between severe and critical illness (p = 0.348). Conclusions: In this study, bradykinin showed a strong negative correlation with disease severity, whereas the ACE/bradykinin ratio showed a strong positive correlation with the severity of COVID-19 suggesting a potential utility of the ACE/bradykinin ratio as a marker of disease severity.
EUVIMED